Ideal for companies within the pharmaceutical and life sciences industries, the solution hopes to solve counterfeit medicine trafficking and false counterfeit challenges.
Distilling new insights from a recent podcast with an industry investor from Nordic Capital, ArisGlobal CEO Aman Wasan makes a robust financial case for advanced automation in processing pharma’s multiplying regulatory and safety workloads.
Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.
Sapio Sciences, the science-aware lab informatics platform, has announced that Schrödinger has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules.
Absci Corporation and Owkin have announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
Michael Burkhard and Amr Eltablawi, Hexagon Asset Lifecycle Intelligence, delve into the top trends shaping pharmaceutical and life sciences operations in 2025.
Owkin has launched its latest report, State of the Nation: Opportunities and Challenges for Digital Pathology and AI Solutions, exploring the evolving landscape of digital pathology and AI in healthcare in the UK.
ArisGlobal’s director of product management’s Agnes Cwienczek, reports on AI-boosted regulatory process automation and other top-level findings from a new Censuswide survey of senior life sciences regulatory professionals.
A new report commissioned by LogiPharma, has revealed the growing impact of artificial intelligence (AI) and machine learning (ML) on pharmaceutical supply chains, highlighting AI’s shift from a “nice-to-have” to a strategic necessity.
Editor Rebekah Jordan spoke to Kevin Kreutter, Ph.D., senior vice president, Drug Discovery, Empress Therapeutics about how the company is using AI to analyse genetic data, to accelerate and refine small molecule drug discovery.
Sonrai is working to bring its innovative cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH), enabling vast and complex data for more meaningful insights.
